Bupropion

BioCorRx Reports Business Update for 2023

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Substance abuse, Bupropion, CFO, Risk, Public, OUD, Research, Security (finance), Opioid use disorder, NIH, Naltrexone, Bangladesh Technical Education Board, MUD, OTCQB, Pharmaceutical industry

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid use disorder (OUD).
  • We successfully decreased our total operating expenses by over $1.0 million for the year ending December 31, 2023, compared to the previous year.
  • Overall, we are optimistic about the business outlook and look forward to continuing to develop medicines.

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

Retrieved on: 
Wednesday, February 28, 2024
CFO, Bangladesh Technical Education Board, OTCQB, Pew, Research, NIH, Naltrexone, Risk, Prevalence, MUD, Disorder, CDC, Bupropion, Pharmaceutical industry

Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines.

Key Points: 
  • Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines.
  • MUD represents a significant public health concern, with devastating consequences for individuals, families, and communities across the country.
  • Despite the growing prevalence of MUD, effective treatment options remain limited, underscoring the urgent need for innovative approaches to address this complex and challenging condition.
  • Currently, there are no approved medications for MUD, and populations at risk of methamphetamine-involved overdose deaths are diversifying.

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Blood pressure, Patient, Medical Subject Headings, Marketing, European Commission, Agency, INN, Weight, Constipation, Risk, ATC, Weight loss, Blood, International, Diet, BMI, European, Diabetes, Method, Nausea, Language, Brain, Bupropion, Heart, Dizziness, Naltrexone, Body mass index, Appetite, Food, Kidney, Tablet, Interim, Xerostomia, Select, Human, Safety, Risk management, Anatomy, Medicine, Seizure, Pleasure, Vomiting, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Hims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss

Retrieved on: 
Monday, December 4, 2023
Health, Telemedicine, Virtual Medicine, Fitness & Nutrition, General Health, Vitamins, Supplements, Pharmaceutical, Topiramate, Metformin, Hims & Hers Health, Sleep, Obesity, Depression, Research, NYSE, FACP, Naltrexone, Major trauma, Medication, Psychology, Gambling, Overweight, Patient, Multimedia, FAAP, Movement, FOMA, Motivation, Weight gain, Digital, Weight loss, MD, CDC, SVP, Heart Health Park, Vitamin B12, Birth control, Nursing, Dietary supplement, Behavior, Hers, Bupropion

View the full release here: https://www.businesswire.com/news/home/20231204073836/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231204073836/en/
    Weight Loss by Hims & Hers (Graphic: Business Wire)
    The science-backed Weight Loss by Hims & Hers program is developed with the expert insight of Dr. Primack and a team of clinical experts in obesity medicine, psychology and nutrition.
  • The program offers a well-rounded and more affordable approach to reducing weight by addressing the underlying factors that affect people’s weight – Nutrition, Behavior, Movement and Medical Treatment.
  • Weight Loss by Hims & Hers aims to address these issues by taking on the physical and psychological factors that contribute to weight gain and loss.
  • For more information on Hims & Hers’ weight loss program, please visit https://www.forhers.com/weight-loss and https://www.hims.com/c/wm/introduction .

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates

Retrieved on: 
Tuesday, October 3, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Mental Health, Health Technology, Other Science, Research, Artificial Intelligence, Science, Psilocybin, DMT, Depression, Therapy, Anxiety, Addiction, Collection, Mental health, Bupropion, MDMA, Pharmaceutical industry, Enver Faja

Enveric’s proprietary artificial intelligence (AI) drug-discovery platform, PsyAI™, has accelerated the design of new chemical entities that can be tailored for specific applications in the management of mental health.

Key Points: 
  • Enveric’s proprietary artificial intelligence (AI) drug-discovery platform, PsyAI™, has accelerated the design of new chemical entities that can be tailored for specific applications in the management of mental health.
  • The Psybrary™ portfolio primarily contains compounds built from substituted indolethylamine (e.g., psilocybin and DMT) or phenylethylamine (e.g., MDMA and bupropion) backbones.
  • A wide range of functional groups were added to various positions on these core structures using synthetic chemistry or synthetic biology methods.
  • “Our Psybrary™ portfolio has been the foundation of Enveric’s successful drug discovery programs, which have so far targeted hallucinogenic and non-hallucinogenic indolethylamine derivatives.

Can at-home DNA tests predict how you'll respond to your medications? Pharmacists explain the risks and benefits of pharmacogenetic testing

Retrieved on: 
Saturday, September 16, 2023
Disulfiram-like drug, DNA, Depression, Genetics, CYP2C19, Citalopram, Cancer, Research, Cell, Bangladesh Technical Education Board, Warfarin, Pharmacist, Food and Drug Administration Amendments Act of 2007, Protein, Drug, Patient, Risk, National, Gene, Tobacco, Pharmacogenomics, Vitamin K, Liver, Knowledge, Safety, Bupropion, Food, Genome, Vaccine, Pharmaceutical industry, Dietary supplement, Generic drug, Antibiotics

This variability in drug response is what pharmacogenomic testing hopes to explain by looking at the genes within your DNA.

Key Points: 
  • This variability in drug response is what pharmacogenomic testing hopes to explain by looking at the genes within your DNA.
  • Pharmacogenomics, or PGx, is the study of how genes affect your response to medications.

How do PGx tests work?

    • PGx tests look for variations within the genes of your DNA to predict drug response.
    • There are commercially available PGx tests that patients can have sent directly to their doorstep with or without the involvement of a health care professional.
    • These direct-to-consumer PGx tests collect DNA from either a saliva sample or cheek swab that is then sent to the laboratory.

Limitations of PGx testing

    • PGx testing will not be able to predict how you will respond to all medications for several reasons.
    • PGx tests can predict how you will respond only to medications associated with the genes it tests for.
    • Some drugs are broken down in very complicated pathways entailing multiple proteins and byproducts, and the usefulness of PGx testing for them remains unclear.
    • In other words, PGx testing is predictive rather than deterministic.

Risks of PGx testing

    • PGx testing carries the risk of not telling the whole story of drug response.
    • If variations within the gene are not found, the testing company often assumes the proteins those genes code for function normally.
    • Sharing your PGx test results with all the clinicians involved in your care can help prevent medication failure and improve safety.

Benefits of PGx testing

    • Direct-to-consumer PGx testing can empower patients to advocate for themselves and be an active participant in their health care by increasing access to and knowledge of their genetic information.
    • Patients’ knowledge of their PGx genetic profile has the potential to improve treatment safety.

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Retrieved on: 
Monday, April 10, 2023
Major depressive disorder, Depression, Montgomery–Åsberg Depression Rating Scale, SIV, Brand, Cancer, Cedars-Sinai Medical Center, Medicine, MADRS, CNS, Trial of the century, SAE, MDD, Patient, Ophthalmology, Grammatical mood, Bupropion, CSMC, Phase, ITT, Safety, Pharmaceutical industry

The SIV was an organized meeting to discuss Phase I study protocol with the principal investigator, Scott A. Irwin, M.D., Ph.D. and begin training clinical personnel.

Key Points: 
  • The SIV was an organized meeting to discuss Phase I study protocol with the principal investigator, Scott A. Irwin, M.D., Ph.D. and begin training clinical personnel.
  • ABV-1601, the Phase I open-label study will be conducted with 12 cancer patients with moderate to severe depressive symptoms.
  • The main objective of the study is to evaluate the safety of PDC-1421, the primary active ingredient in ABV-1601, in cancer patients.
  • “We are pleased to see the ABV-1601 Site Initiation Visit successfully completed at Cedars-Sinai Medical Center (CSMC) with Dr. Scott Irwin M.D., Ph.D. and his clinical team,” said Dr. Howard Doong, Chief Executive Officer of the Company.

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Retrieved on: 
Friday, March 31, 2023
San Francisco, Retina, Surgeon, Depression, University, University of California, San Francisco, ADHD, Cancer, Toxicity, Research, Medicine, CNS, Central nervous system, Trial of the century, Net, Suretrack Contracts Services, Stanford University Medical Center, MDD, Patient, UCSF, Medical Center, Grammatical mood, Bupropion, CSMC, Phase, Visual acuity, Deficit, Safety, Pharmaceutical industry, Cryptocurrency, Medical device, Phase II

FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.

Key Points: 
  • FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.
  • Our operating expenses were $15,797,780 in the year ended December 31, 2022, as compared to $12,056,679 in the year ended December 31, 2021.
  • The net loss was $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021.
  • “We are delighted with our remarkable accomplishments and meaningful progress in 2022,” said Dr. Howard Doong, M.D., Ph.D., Chief Executive Officer of ABVC BioPharma.

Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE®

Retrieved on: 
Monday, March 6, 2023
Naltrexone, Smoking, Tablet, III, Naltrexone/bupropion, Obesity, Overweight, ANDA, Telehealth, Advertising, Type 2 diabetes, Weight loss, Patient, Disease, Body mass index, Complaint, Health, FDA, Conditional sentence, BMI, Bupropion, Marketing, Generic drug, Aenictus currax

The complaint alleges that Found Health is engaging in falsely marketing medications to patients as the generic equivalent of CONTRAVE® when no generic equivalent exists.

Key Points: 
  • The complaint alleges that Found Health is engaging in falsely marketing medications to patients as the generic equivalent of CONTRAVE® when no generic equivalent exists.
  • The complaint details numerous federal and state claims including trademark infringement, false advertising, unfair competition, and false designation of origin.
  • "Today we initiated legal action against a telemedicine company caught falsely marketing medications as equivalent to Contrave," said George Hampton, President and CEO of Currax.
  • Offending entities are marketing, identifying, prescribing, and distributing different dosages of naltrexone and bupropion tablets as CONTRAVE®, a CONTRAVE® equivalent, and/or a CONTRAVE® generic.

ABVC BioPharma Provides 2023 Pipeline Update

Retrieved on: 
Tuesday, February 28, 2023
Medicine, Shirin David, Cancer, Memorial Sloan Kettering Cancer Center, Medical Center, IND, CSMC, Myelodysplastic syndrome, Trial of the century, Stanford University Medical Center, Center for Drug Evaluation and Research, Safety, Massachusetts General Hospital, Patient, Central nervous system, Psychiatry, Hospital, Phase, University of California, San Francisco, Grammatical mood, University, Depression, UCSF, Regulation, Research, San Francisco, CNS, MGH, Cedars-Sinai Medical Center, US, Pancreatic cancer, Visual acuity, Lung cancer, FDA, Ophthalmology, Bupropion, Harvard Medical School, Division, ADHD, MDD, Pharmaceutical industry, Nursing, Phase II

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.

Key Points: 
  • FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.
  • ABVC expects to initiate the Phase II study in the fourth quarter of 2023 and then compare the results to Wellbutrin XL, a commonly used medicine to treat cancer patients suffering with depression.
  • The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023.
  • In addition, ABVC intends to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States.